Skip to main content

Table 4 Prospective evaluation of the EGFR status of exons 19 and 21

From: Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC

% of tumoral tumoral samples (n = 206) EGFR mutations (n = 18)  
cells number % exon 19 exon 21 %
<20% 36 17.5 0 1 2.8
from 20 to 50% 98 47.6 3 6 9.2
>50% 72 35 5 3 11.1
  1. Samples may contain at least 20% of tumor cells to allow a correct detection of mutations